Sirtuins — the longevity proteins and what they actually do

That question has occupied an enormous amount of biology over the twenty-five years since.

Sir2 turned out to be the founding member of a family of proteins — now called sirtuins — that are conserved across virtually every domain of life. In mammals, there are seven of them, designated SIRT1 through SIRT7, and they are not all alike. They sit in different cellular compartments: SIRT1, SIRT6, and SIRT7 are primarily nuclear; SIRT2 is cytoplasmic; SIRT3, SIRT4, and SIRT5 live in the mitochondria. Their distribution across the cell's geography matters because each compartment has different problems to manage and different substrates to act on. What unifies the family is a conserved enzymatic mechanism and, broadly, a conserved orientation toward cellular maintenance.

The mechanism is the part that surprised researchers when it was first characterized. Sirtuins are NAD+-dependent deacetylases. This means they remove acetyl groups from target proteins — but only when NAD+, a form of nicotinamide adenine dinucleotide, is present as a co-substrate. NAD+ is not simply an energy carrier here in the way it functions in glycolysis and the citric acid cycle. It is consumed during each deacetylation reaction: one molecule of NAD+ is used per deacetylation event, yielding nicotinamide and a molecule called O-acetyl-ADP-ribose. This consumption creates a direct molecular link between sirtuin activity and the cell's energetic state. When NAD+ is abundant — as it tends to be during caloric restriction, fasting, or vigorous exercise — sirtuins are more active. When NAD+ is depleted, as it increasingly is with aging, sirtuin activity falls. The connection between energy availability and longevity regulation runs through this metabolic coupling, and it turns out to be one of the more important facts in aging biology.

Beyond deacetylation, some sirtuins perform other enzymatic reactions. SIRT4 performs ADP-ribosylation of targets in the mitochondria. SIRT5 is a desuccinylase and demalonylase. The diversity of enzymatic activities means the family's reach is wider than simple histone deacetylation — though that function, concentrated in SIRT1 and SIRT6, is among the most consequential.

Histone deacetylation is how sirtuins reach into the epigenome. Histones are the protein spools around which DNA is wound, and acetylation of histones generally loosens the chromatin structure, making genes more accessible for transcription. When SIRT1 and SIRT6 remove those acetyl marks, chromatin compacts again, silencing nearby genes. This is a form of epigenetic regulation: the DNA sequence hasn't changed, but which genes are readable has. The relevance to aging is significant because aging is in part an epigenetic phenomenon — the pattern of which genes are expressed and which are silenced shifts with age in characteristic ways. Sirtuins are among the regulators that maintain appropriate chromatin architecture, and their declining activity with age may contribute to the epigenetic drift that characterizes older tissues.

But sirtuins don't only act on histones. They deacetylate a wide array of transcription factors, and this is where their effects ramify into metabolism, stress response, and longevity signaling. SIRT1 deacetylates FOXO transcription factors, which govern genes for stress resistance and autophagy. It deacetylates p53, the tumor suppressor, modulating how cells respond to DNA damage. It deacetylates PGC-1alpha, the master regulator of mitochondrial biogenesis, affecting how many mitochondria a cell makes and how efficiently they operate. Each of these substrates connects to a branch of biology relevant to aging and disease: genomic stability, programmed cell death, energy metabolism, inflammation. The list is not short, and SIRT1 alone has well over a hundred identified substrates in the literature. This breadth is why sirtuins came to be framed as master regulators — though the framing, as often happens in biology, somewhat outran the evidence.

The caloric restriction connection is where sirtuin biology first made contact with the ancient observation that animals fed less live longer. Caloric restriction — reducing caloric intake by roughly thirty percent without malnutrition — extends lifespan in organisms from yeast to rodents and improves healthspan markers in primates, including humans. The mechanism was contested for decades. One prominent hypothesis, developed in part through Guarente's work, was that caloric restriction works largely by activating sirtuins. The argument was mechanistically tidy: CR raises NAD+ levels by altering the AMP/ATP ratio and related metabolic signals; elevated NAD+ activates sirtuins; sirtuins deacetylate their targets and shift cells toward maintenance and repair programs. CR becomes a metabolic signal that the sirtuin network translates into a longevity program.

This hypothesis has been complicated but not dismantled. Work in yeast supported it strongly. Work in mammals produced mixed results depending on genetic background, the specific sirtuin studied, and what endpoints were measured. SIRT1 knockout mice don't show the expected attenuation of CR benefits in every study, suggesting that CR may route through multiple parallel mechanisms rather than through sirtuins alone. The current understanding is that sirtuins mediate some — probably significant — portion of CR's effects, particularly in the epigenetic and metabolic dimensions, while other pathways including mTOR inhibition and AMPK activation run alongside them. The honest answer is that these pathways are not cleanly separable in a living organism.

Then there is resveratrol, which became a cultural phenomenon before the biology had settled. Resveratrol is a polyphenol found in red wine and grape skins, and in 2003 David Sinclair's lab — Sinclair having trained in Guarente's lab — published a paper in Nature reporting that resveratrol activated SIRT1 and extended lifespan in yeast. The paper landed in popular culture as the molecular explanation for the French Paradox, the observation that French people ate saturated fat and drank red wine and appeared to have lower cardiovascular disease rates than expected. Suddenly there was a mechanism: SIRT1 activation. Red wine sales presumably benefited.

The controversy that followed was substantive. A group at Pfizer and independent researchers published work arguing that the assay Sinclair's lab used to detect SIRT1 activation was an artifact: resveratrol appeared to activate SIRT1 in the fluorescence-based assay because it interacted with the fluorescent tag on the substrate peptide, not because it was a genuine allosteric activator of the enzyme. Using untagged, native substrates, the Pfizer group reported they couldn't reproduce the direct activation. The implication was damaging — if resveratrol's SIRT1 activation was a methodological artifact, the molecular rationale for the entire story collapsed.

Sinclair's lab and collaborators pushed back. They published work showing that resveratrol could activate SIRT1 under conditions not dependent on the fluorescent tag, and that the Pfizer group's untagged substrates may have differed in ways that mattered. The dispute was partly methodological — different substrates, different assay conditions — and partly about whether any residual real activation was large enough to be biologically meaningful. The current position in the field is cautious: resveratrol almost certainly doesn't activate SIRT1 the way a precise allosteric activator would, but it may have indirect effects on the NAD+ pool and sirtuin activity through other mechanisms. Whether those effects are significant enough to matter at doses achievable through food or even supplementation remains genuinely uncertain. The amounts of resveratrol in red wine are orders of magnitude below what any longevity effect in mice required.

The SRT compounds — SIRT1-activating compounds developed by Sirtris Pharmaceuticals, which Sinclair co-founded and which was later acquired by GlaxoSmithKline — were more potent than resveratrol in biochemical assays, but their clinical development was complicated by similar debates about mechanism and by disappointing trial results in myeloma. The larger SRT program has not produced approved drugs.

Where sirtuin research has found firmer ground is in the NAD+ connection. The logic runs as follows: sirtuins require NAD+ to function; cellular NAD+ levels decline with age — measurably, across tissues, in rodents and in humans — due to decreased biosynthesis, increased consumption by competing enzymes like PARP and CD38, and potentially reduced salvage efficiency; declining NAD+ limits sirtuin activity even when the sirtuins themselves are still present and structurally intact. This creates a potential intervention point: if NAD+ levels could be restored through dietary precursors, sirtuin activity might be partly restored as well.

The NAD+ precursors of interest are primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both of which are converted through the cell's biosynthetic machinery to NAD+. Human trials of both compounds have consistently shown that oral supplementation raises blood and tissue NAD+ levels in older adults — this part is established. Whether that elevation meaningfully restores sirtuin activity in the specific tissues and compartments that matter for aging outcomes is a harder question, and the human trial data on downstream biological outcomes is more preliminary. The NMN trial landscape includes work suggesting modest improvements in muscle function, walking speed, and insulin sensitivity in older adults, but the effect sizes are not large and the number of well-powered studies is limited. NAD+ is also consumed by enzymes other than sirtuins — PARP enzymes, CD38, and others — so elevating it doesn't exclusively route through sirtuin pathways.

SIRT3, the primary mitochondrial sirtuin, deserves particular attention because its biology connects sirtuin function to mitochondrial health in a way that directly affects cellular energy capacity. SIRT3 deacetylates and activates multiple components of the mitochondrial electron transport chain and TCA cycle, including components of complex I and the key antioxidant enzyme MnSOD. SIRT3 knockout mice develop metabolic syndrome, hearing loss, and increased cancer risk more quickly than wild-type controls. Its decline with age appears to contribute to the mitochondrial dysfunction that is itself one of the recognized hallmarks of aging. Here the sirtuin story and the mitochondrial biology story converge in a way that doesn't depend on resolving the resveratrol controversy.

SIRT6 is another sirtuin whose biology has attracted significant attention. It is a prominent player in DNA damage repair — it localizes to sites of double-strand breaks and facilitates repair by deacetylating histones and recruiting repair machinery. SIRT6 overexpression extends lifespan in male mice. SIRT6 deficiency produces an accelerated aging phenotype. Its activity in maintaining genomic stability connects sirtuin biology to another of aging's recognized hallmarks: the accumulation of DNA damage over time.

The honest middle on sirtuins is this: the biology is robust in ways that decades of research have validated, refined, and deepened. Sirtuins are real regulators of real aging-related processes — histone deacetylation, transcription factor modulation, DNA repair, mitochondrial function, stress response. They connect the cell's energetic state to its maintenance programs through the NAD+ dependency in a way that is molecularly precise and conserved across evolution. The caloric restriction connection is real, even if it is not the entire story of why CR works. The NAD+ decline with aging is real, and its potential to limit sirtuin activity is mechanistically sound.

What remains to be established is the specific translation to human longevity outcomes from sirtuin-targeted interventions. The mouse longevity studies are suggestive but not straightforwardly extrapolated to humans. The resveratrol story has complicated the field's credibility with the general public in ways that weren't entirely fair to the underlying biology. The NAD+ precursor data in humans is promising but not yet definitive on downstream longevity endpoints. This gap between robust mechanism and confirmed human outcome is not unusual in aging biology — it is, in fact, the rule — but it matters for interpreting what any particular intervention can currently claim to do.

What sirtuins ultimately teach is that aging is metabolic before it is inevitable. The same metabolic signals that tell the cell it has energy — NAD+, the AMP/ATP ratio, the availability of acetyl-CoA — are feeding information to the machinery that decides how the cell maintains itself. Caloric restriction, exercise, fasting: these are not simply lifestyle choices that happen to correlate with better health. They are inputs into a signaling network whose output is the epigenome, the mitochondria, the DNA repair apparatus. Sirtuins are not the only component of that network, and they are not yet a confirmed handle for extending human lifespan. But they are a window through which the relationship between how a cell feeds and how long it lives becomes, for the first time, mechanistically legible.